Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months

Authors

  • Laura Cannella Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
  • Massimo Breccia Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
  • Giuseppina Loglisci Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
  • Vincenzo Federico Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
  • Michelina Santopietro Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
  • Giuliana Alimena Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy

DOI:

https://doi.org/10.3109/02841860903521129

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2010-01-01

How to Cite

Cannella, L., Breccia, M., Loglisci, G., Federico, V., Santopietro, M., & Alimena, G. (2010). Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months. Acta Oncologica, 49(3), 399–400. https://doi.org/10.3109/02841860903521129

Issue

Vol. 49 No. 3 (2010): Acta Oncologica

Section

Articles